Improving cancer survival and quality of life
Initial focus on hematologic malignancies and gynaecologic cancers
Ojjaara
(momelotinib)
• Approved in the US as the first
and only treatment indicated
for MF
2
patients with anaemia
• Nearly all MF patients are
estimated to develop anaemia
• EU marketing authorisation
expected early 2024
• Potential to become a
backbone therapy in MF due to
differentiated MOA
• Combinations and future
indications under evaluation
Zejula
(niraparib)
• Assessing activity across
multiple tumour types and in
combination with other
therapeutics
• Combination treatment in
endometrial cancer positive
data in house
• Combination treatment in
ovarian cancer, data expected
in 2024
• Maintenance treatment in
ovarian cancer, data expected
in 2024
• Maintenance treatment in
NSCLC, data expected in 2024
Jemperli
(dostarlimab)
• Ambition to be the backbone of
our ongoing immuno-oncology
research
• Combination treatment in
endometrial cancer approved
in US, EU with part one data to
be presented in 2024 and
positive part 2 data in house;
monotherapy data is expected
in 2027
• Combination treatment with
cobolimab, an anti-TIM3, in
NSCLC
1
, data expected 2024
• Treatment in rectal cancer,
data expected in 2027
Additional pipeline assets
9
1. Non-small cell lung cancer 2. Myelofibrosis 3. Relapse or refractory multiple myeloma
• Exclusive license agreements
with Hansoh for two novel
antibody-drug conjugates for
gynaecologic cancers and
broader solid tumour
indications
• Blenrep positive headline results
for DREAMM-7 in second-line
treatment for RRMM
3
;
DREAMM-8 data in H2 2024
• Cobolimab, an anti-TIM3
antagonist in phase III in
combination with Jemperli for
treatment of NSCLC
• Exploring novel combinations
that act on all major targets of
the CD226 axis; blocking these
may help the immune system
better target tumour cells